Outlook Therapeutics Faces a July of Two Reckonings: Shareholder Vote and FDA Verdict

Outlook Therapeutics must secure shareholder approval for capital restructuring by July 15 ahead of a crucial FDA verdict on its eye drug LYTENAVA on July 29, amid financial distress and high dilution risk.

Two pivotal events separated by just a fortnight will determine the trajectory of Outlook Therapeutics this month. First, shareholders must cast their votes by July 15 on a trio of capital restructuring proposals. Then on July 29, the FDA is scheduled to deliver its verdict on the company’s eye drug LYTENAVA (ONS-5010). The stock, which closed Thursday at $1.47, edged up 3.06% to $1.51 the following day — a modest rebound in a name that has seen 30-day volatility of over 233% annualized.

The financial backdrop is precarious. Outlook Therapeutics ended March with just $7.7 million in cash, and management has acknowledged “substantial doubt” about its ability to continue as a going concern. An April registered direct placement brought in $5.0 million gross (or $4.5 million net, depending on the source), alongside a new at-the-market offering facility with H.C. Wainwright for up to $100 million — though the bank takes a 3% commission on all proceeds. The company’s most recent quarterly revenue came in at a paltry $127,400, with trailing twelve-month sales of $1.4 million, largely from early European sales. On the brighter side, the net loss for the second quarter of fiscal 2026 shrank sharply to $4.5 million from $46.4 million a year earlier.

Three Questions, One Ballot

The shareholder meeting is scheduled for July 16 at 9 a.m. Central Time in Chicago, at the offices of law firm Cooley LLP. Votes must be submitted by 11:59 p.m. Eastern on July 15. The ballot contains three items: first, authorizing the issuance of common shares upon exercise of warrants from a private placement and placement agent agreements; second, increasing authorized shares from 260 million to 600 million; and third, granting the board authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50, with a proportional reduction in authorized shares.

Management frames these measures as essential to securing future financing. If approved, the warrants — exercisable at $0.31 from the April round — could unlock roughly $6.1 million in additional proceeds. But the proposals carry significant dilution risk. The authorized share count would more than double, and the reverse split, while designed to keep the stock above Nasdaq’s $1 minimum bid, would be paired with a reduction in the authorized pool in an attempt to limit excessive future dilution.

Nasdaq Compliance Regained, But the Safety Net Remains

The reverse split request first emerged under the shadow of a delisting threat. On February 18, 2026, Nasdaq warned Outlook that its stock had traded below $1 for 30 consecutive sessions. That immediate danger has since passed. On June 26, the exchange confirmed that the shares had closed at or above $1 for ten straight trading days between June 11 and June 25, restoring compliance.

Still, the company wants the reverse split authorization as a defensive tool rather than an immediate action. The stock’s recent jump — it has surged more than 86% over the past 30 days and over 129% year-to-date — has lifted it well above the critical threshold. At $1.51, it trades 93.93% above its 50-day moving average of $0.76, but remains roughly half its 52-week high of $2.97 from August 2025. The 52-week low was $0.16 in late March.

If shareholders reject the proposals, management has warned of layoffs, program cuts, or even bankruptcy. The cash runway is simply too short to sustain operations through a prolonged FDA review without tapping new capital.

FDA Decision: The Second Trigger

Just 13 days after the shareholder vote, the FDA will release its decision on LYTENAVA under a Class-1 resubmission. The path to this moment was cleared when the FDA’s Office of New Drugs ruled in Outlook’s favor during a formal dispute resolution process, concluding that the NORSE TWO trial plus confirmatory evidence provided sufficient efficacy data for LYTENAVA in wet age-related macular degeneration. The agency subsequently instructed its review divisions to work toward final labeling agreements with the company.

An approval would resolve the regulatory question, but not the commercial one. LYTENAVA already has marketing authorization in the European Union and the United Kingdom, with sales underway in Germany and Austria. Outlook has secured an exclusive distributor to enter the Swiss market in 2027. In the US, however, it would face a market dominated by cheaper off-label alternatives, making pricing and reimbursement crucial hurdles even after a green light.

The stock’s extreme volatility — 233% annualized over 30 days — reflects the binary nature of these twin events. A failed shareholder vote would strip the company of the capital tools it needs to capitalize on a positive FDA ruling, while a successful vote would still leave the business dependent on the agency’s verdict. Either way, July promises to be a month of reckoning for Outlook Therapeutics.